14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.25 $5.48 Wednesday, 1st May 2024 QURE stock ended at $4.57. This is 3.63% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 6.31% from a day low at $4.36 to a day high of $4.64.
90 days $4.25 $6.85
52 weeks $4.25 $22.48

Historical uniQure N.V. prices

Date Open High Low Close Volume
Dec 09, 2021 $30.01 $30.41 $28.02 $28.03 424 221
Dec 08, 2021 $29.01 $29.48 $28.22 $29.35 250 647
Dec 07, 2021 $27.96 $29.23 $27.93 $28.80 430 667
Dec 06, 2021 $27.07 $28.02 $26.06 $27.88 487 861
Dec 03, 2021 $27.38 $27.82 $26.73 $27.14 342 613
Dec 02, 2021 $26.51 $27.79 $26.51 $27.43 485 300
Dec 01, 2021 $27.89 $28.69 $26.42 $26.42 371 374
Nov 30, 2021 $28.27 $28.80 $27.30 $27.85 339 809
Nov 29, 2021 $29.10 $29.65 $28.36 $28.52 420 777
Nov 26, 2021 $28.38 $29.05 $27.94 $28.82 225 309
Nov 24, 2021 $27.92 $29.16 $27.66 $29.09 240 881
Nov 23, 2021 $28.57 $28.89 $27.39 $28.12 502 735
Nov 22, 2021 $29.86 $29.87 $28.69 $28.82 317 396
Nov 19, 2021 $29.25 $29.85 $29.00 $29.64 735 724
Nov 18, 2021 $29.93 $30.34 $28.83 $29.25 332 797
Nov 17, 2021 $30.75 $30.75 $29.76 $29.93 819 572
Nov 16, 2021 $31.06 $31.39 $30.52 $31.06 237 041
Nov 15, 2021 $31.81 $32.05 $30.81 $31.08 338 966
Nov 12, 2021 $33.02 $33.03 $31.76 $31.97 245 225
Nov 11, 2021 $33.80 $34.12 $32.80 $32.80 196 976
Nov 10, 2021 $34.57 $35.55 $33.40 $33.72 269 607
Nov 09, 2021 $35.20 $35.68 $34.45 $34.57 197 547
Nov 08, 2021 $35.31 $36.21 $35.28 $35.53 256 964
Nov 05, 2021 $36.05 $36.55 $34.64 $35.23 280 619
Nov 04, 2021 $35.90 $36.21 $35.01 $36.01 401 280
Click to get the best stock tips daily for free!

About uniQure N.V.

uniQure N.V. uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas... QURE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT